Jazz Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | JAZZ
Jazz Pharmaceuticals retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $0.872B, a 7.3% increase year-over-year.
- Jazz Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $0.879B, a 19.76% increase from 2022.
- Jazz Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $0.734B, a 11.63% decline from 2021.
- Jazz Pharmaceuticals retained earnings (accumulated deficit) for 2021 were $0.831B, a 28.41% decline from 2020.